Neuroblastoma screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Neuroblastoma}} | {{Neuroblastoma}} | ||
{{CMG}} {{AE}}{{HL}} | {{CMG}} {{AE}}{{HL}}{{ZAS}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits. | There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits. | ||
==Screening== | ==Screening== | ||
* There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.<ref name="US">Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015</ref> | * There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.<ref name="US">Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015</ref><ref>{{Cite journal | ||
| author = [[William G. Woods]], [[Ru-Nie Gao]], [[Jonathan J. Shuster]], [[Leslie L. Robison]], [[Mark Bernstein]], [[Sheila Weitzman]], [[Greta Bunin]], [[Isra Levy]], [[Josee Brossard]], [[Geoffrey Dougherty]], [[Mendel Tuchman]] & [[Bernard Lemieux]] | |||
| title = Screening of infants and mortality due to neuroblastoma | |||
| journal = [[The New England journal of medicine]] | |||
| volume = 346 | |||
| issue = 14 | |||
| pages = 1041–1046 | |||
| year = 2002 | |||
| month = April | |||
| doi = 10.1056/NEJMoa012387 | |||
| pmid = 11932470 | |||
}}</ref> | |||
==References== | ==References== | ||
Revision as of 16:18, 14 February 2019
|
Neuroblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuroblastoma screening On the Web |
|
American Roentgen Ray Society Images of Neuroblastoma screening |
|
Risk calculators and risk factors for Neuroblastoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2] Zahir Ali Shaikh, MD[3]
Overview
There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits.
Screening
- There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.[1][2]
References
- ↑ Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015
- ↑ William G. Woods, Ru-Nie Gao, Jonathan J. Shuster, Leslie L. Robison, Mark Bernstein, Sheila Weitzman, Greta Bunin, Isra Levy, Josee Brossard, Geoffrey Dougherty, Mendel Tuchman & Bernard Lemieux (2002). "Screening of infants and mortality due to neuroblastoma". The New England journal of medicine. 346 (14): 1041–1046. doi:10.1056/NEJMoa012387. PMID 11932470. Unknown parameter
|month=ignored (help)